Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: Data are safer than extrapolations

Ivo Abraham, Karen MacDonald

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations
Original languageEnglish (US)
Pages (from-to)885-887
Number of pages3
JournalExpert Opinion on Drug Safety
Issue number6
StatePublished - Nov 1 2012


  • Chronic kidney disease
  • End-stage renal disease
  • Erythropoiesis-stimulating agents
  • Erythropoietin
  • Safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this